NCT05029076

Human Bioequivalence Test of Liraglutide Injection

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

To evaluate the bioequivalence of The liraglutide injection produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Victoza® produced by Novo Nordisk (China) Pharmaceutical Co., Ltd for single dose in healthy subjects,so as to provide reference for clinical evaluation and clinical medication;To observe the safety of the test preparation liraglutide injection and the reference preparation Victoza ® in healthy subjects.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Liraglutide injection	Human glucagon-like peptides-1 analogue
DRUG	Victoza	Human glucagon-like peptides-1 analogue

Timeline

• Start date: 2019-05-21
• Primary completion: 2019-06-01
• Completion: 2019-07-01
• First posted: 2021-08-31
• Last updated: 2021-08-31

Locations

1 site across 1 country: China